达比加群酯血药浓度监测及药学监护的研究进展  

RESEARCH PROGRESS IN OLASMA CONCENTRATION MONITORING AND PHARMACEUTICAL CARE OF DABIGATRAN ETEXILATE

作　　者：杨蕾 董至恒 徐智宇[1] 董大千 YANG Lei;DONG Zhiheng;XU Zhiyu;DONG Daqian(Department of Pharmacy,The Afiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China;College of Pharmacy,Inner Mongolia Medical University,Hobhot 010059,China)

机构地区：[1]内蒙古医科大学附属医院药学部,内蒙古呼和浩特010050 [2]辽宁省人民医院药学部,辽宁沈阳110000

出　　处：《内蒙古医科大学学报》2024年第6期645-650,共6页Journal of Inner Mongolia Medical University

基　　金：国家自然科学基金项目(82160703);内蒙古自治区自然科学基金项目(2020MS08106)。

摘　　要：达比加群酯是一种新型的口服抗凝药,通过在肝脏水解为达比加群而发挥治疗效果。与传统口服抗凝剂相比,其具有无需进行常规监测、与食物-药物相互作用小、给药剂量恒定等特点。尽管如此,在特定情况下,仍然需要对其浓度进行监测。有研究表明,肝肾功能不全、老年患者、不同体质、出血风险较高或与其他药物治疗并存的情况下影响达比加群的血药浓度。本文旨在全面阐述达比加群血药浓度的影响因素、监测方法、在不同患者群体中的治疗窗范围以及相关的药学监护的研究进展。通过上述研究,旨在为临床上合理应用达比加群提供全面、客观的参考依据。Dabigatran etexilate,a novel oral anticoagulant that exerts its therapeutic effects through hepatic hydrolysis into dabigatran.Compared to traditional oral anticoagulants,it has characteristics such as no need for routine monitoring,a low-probability of drug-drug and food-drug interactions,and a constant dosage.Nevertheless,in specific circumstances,monitoring of its concentration is still necessary,such as in patients with impaired liver or kidney function,elderly individuals,those with different physiques,increased risk of bleeding,or when co-administered with other medications.This article aims to compre-hensively elucidate the factors influencing dabigatran concentration,monitoring methods,therapeutic ranges in diverse patient populations,and advancements in related pharmaceutical care.Through this research,the objective is to provide a comprehen-sive and objective reference for the rational application of dabigatran in clinical settings.

关 键 词：达比加群酯 血药浓度监测 药学监护 新型口服抗凝药 

分 类 号：R917[医药卫生—药物分析学]